Eastgate Biotech Corp



PE Ratio
Market Cap
52 Week Range
$0 - $0.0075
Operating Margin
Dividend & Yield
$0 (0.00%)
Rev. per Share

About Eastgate Biotech Corp

Eastgate Biotech Corp., a development stage company, develops novel formulations of natural compounds and pharmaceutical products. The company is developing pharmaceutical products, such as Lorazepam oral spray for acute seizures emergency treatment; Ketoconazole 2% topical ointment for treatment of skin fungal infections; and Metformin chewable/ sublingual tablets for treatment of type 2 diabetes. It is also developing natural products and dietary supplements, including E-drops Nano and PURALEN that are self-nanoemulsifying compositions containing natural essential oils for oral administration; Glucora, a soft gelatin capsule with Banaba extract in self-emulsifying formulation for oral administration; URBAN POWER, a soft gelatin capsule with Ursolic acid and Banaba extract in self-emulsifying formulation for oral administration; Vitamin D3 nanoemulsion, a nanoemulsion with cholecalciferol; and Cleanezze, a hand sanitizer containing oil. Eastgate Biotech Corp. has collaboration with Biotech Corp. to develop a vaccine against COVID-19. The company was formerly known as Eastgate Acquisitions Corporation and changed its name to Eastgate Biotech Corp. in December 2014. Eastgate Biotech Corp. was founded in 1999 and is based in Toronto, Canada.


News about Eastgate Biotech Corp

Eastgate Biotech Corp

About kinfo
Kinfo is an app for DIY traders and investors. Kinfo tracks your trading performance and lets you compare measurable performance metrics against other traders. Kinfo works for day trading, swing trading and longer holding periods. By tracking portfolio performance kinfo allows traders to learn, find inspiration and gain confidence.
Get Social
Download the App

Trading involves significant risk of loss. It is not suitable for all investors and you should make sure you understand the risks involved, seeking independent advice if necessary.

Never risk more than you are willing to lose. Trading futures and other derivatives may cause losses that exceed deposits.

Hypothetical performance results have inherent limitations, some of which are described below. Kinfo makes no representation that any trading account will or is likely to achieve profits or losses like those shown. There are often sharp differences between hypothetical trading performance results and the actual results subsequently achieved by any trading program. Past results of advertised trading systems, profit statements, charts or any other representations are not indicative of future performance.

Kinfo is an educational site and is not a financial adviser or broker. All stocks, ETFs, commodities, Indices, Forex, Bonds, and other securities mentioned in our courses are for educational and illustrative purposes only. If you need professional investment advice, please consult a registered investment adviser. Futures and Options carry risk and may not be suitable for everyone.

Kinfo demonstrates specific advanced approaches (or methods). Any mention of Return of Investment percentages is only indicative of the potential of the strategy or the system and is not meant to signify any guaranteed returns.

Success in trading involves a range of human factors like decision making skills, adjustment skills, emotional control, and risk management and other psychological and behavioral parameters, all of which are completely in the hands of the individual. Trading involves significant risk of loss. It is not suitable for all investors.

Charts on kinfo provided by TradingView